FDA Clears Cepheid's Xpert CT/NG Test | GenomeWeb

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has cleared Cepheid's Xpert CT/NG test for marketing, the Sunnyvale, Calif.-based company announced after the close of the market on Thursday.

The test for the rapid detection and differentiation of chlamydia and Neisseria gonorrhoeae runs on Cepheid's GeneXpert system and allows for the same-day patient consultation and treatment of the two most common sexually transmitted bacterial infections in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.